Interventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review.

IF 0.6 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Reinhard Janssen-Aguilar, Shakila Meshkat, Huda F Al-Shamali, Argyrios Perivolaris, Jennifer Swainson, Yanbo Zhang, Andrew Greenshaw, Lisa Burback, Olga Winkler, Jennifer L Phillips, Murray W Enns, Jitender Sareen, Andrew Nicholson, Eric Vermetten, Rakesh Jetly, Ruth Lanius, Venkat Bhat
{"title":"Interventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review.","authors":"Reinhard Janssen-Aguilar, Shakila Meshkat, Huda F Al-Shamali, Argyrios Perivolaris, Jennifer Swainson, Yanbo Zhang, Andrew Greenshaw, Lisa Burback, Olga Winkler, Jennifer L Phillips, Murray W Enns, Jitender Sareen, Andrew Nicholson, Eric Vermetten, Rakesh Jetly, Ruth Lanius, Venkat Bhat","doi":"10.5152/pcp.2025.241027","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Posttraumatic stress disorder (PTSD) is a severe, often difficult-to-treat condition, highlighting the need for innovative therapies. Interventional treatments, including neuromodulation, rapid-acting pharmacotherapies such as intravenous ketamine (IV-KET) and esketamine (ESK), and emerging psychedelic-assisted psychotherapies, offer promising solutions. This systematic review evaluates the efficacy, safety, and future research priorities of these treatments for PTSD.</p><p><strong>Methods: </strong>A search strategy was implemented across 3 electronic databases. Peer-reviewed articles written in English that focused on interventional psychiatry treatments for adult patients with PTSD were included.</p><p><strong>Results: </strong>The systematic review encompassed 94 studies, including 39 on transcranial magnetic stimulation (TMS), 8 on IV-KET, 3 on intranasal esketamine (IN-ESK), 4 on intravenous ketamine (IV-KET) assisted therapy (KET-AT), 1 on esketamine (ESK) assisted therapy (ESK-AT), and 14 on 3,4-methylenedioxymethamphetamine assisted therapy (MDMA-AT). Randomized controlled trials demonstrated response rates of 12.5%-80% for TMS, 17%-67% for IV-KET, and 50%-87% for MDMA. Additional treatments reviewed included Electroconvulsive Therapy, transcranial direct current stimulation, and other pharmacological and neurostimulation treatments. Most treatments were well tolerated, with only mild, transient adverse effects.</p><p><strong>Conclusions: </strong>This review highlights the heterogeneity in efficacy, safety, and tolerability across neuromodulation and pharmacologic treatments for PTSD. Variability in response rates reflects differences in patient populations, protocols, and comorbidities. While repetitive TMS, IV-KET, ESK, KET-AT, and MDMA-AT show symptom improvement, sustained efficacy varies, underscoring the need for maintenance strategies. Although direct evidence on stage-specific approaches is limited, these methods, guided by neuroscience-based nomenclature, may improve therapeutic precision, especially in complex cases.</p>","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"35 Suppl 1","pages":"S57-S89"},"PeriodicalIF":0.6000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410247/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry and Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5152/pcp.2025.241027","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Posttraumatic stress disorder (PTSD) is a severe, often difficult-to-treat condition, highlighting the need for innovative therapies. Interventional treatments, including neuromodulation, rapid-acting pharmacotherapies such as intravenous ketamine (IV-KET) and esketamine (ESK), and emerging psychedelic-assisted psychotherapies, offer promising solutions. This systematic review evaluates the efficacy, safety, and future research priorities of these treatments for PTSD.

Methods: A search strategy was implemented across 3 electronic databases. Peer-reviewed articles written in English that focused on interventional psychiatry treatments for adult patients with PTSD were included.

Results: The systematic review encompassed 94 studies, including 39 on transcranial magnetic stimulation (TMS), 8 on IV-KET, 3 on intranasal esketamine (IN-ESK), 4 on intravenous ketamine (IV-KET) assisted therapy (KET-AT), 1 on esketamine (ESK) assisted therapy (ESK-AT), and 14 on 3,4-methylenedioxymethamphetamine assisted therapy (MDMA-AT). Randomized controlled trials demonstrated response rates of 12.5%-80% for TMS, 17%-67% for IV-KET, and 50%-87% for MDMA. Additional treatments reviewed included Electroconvulsive Therapy, transcranial direct current stimulation, and other pharmacological and neurostimulation treatments. Most treatments were well tolerated, with only mild, transient adverse effects.

Conclusions: This review highlights the heterogeneity in efficacy, safety, and tolerability across neuromodulation and pharmacologic treatments for PTSD. Variability in response rates reflects differences in patient populations, protocols, and comorbidities. While repetitive TMS, IV-KET, ESK, KET-AT, and MDMA-AT show symptom improvement, sustained efficacy varies, underscoring the need for maintenance strategies. Although direct evidence on stage-specific approaches is limited, these methods, guided by neuroscience-based nomenclature, may improve therapeutic precision, especially in complex cases.

Abstract Image

Abstract Image

Abstract Image

创伤后应激障碍(PTSD)的介入精神病学和新兴治疗方法:系统综述。
背景:创伤后应激障碍(PTSD)是一种严重的、通常难以治疗的疾病,强调了创新治疗的必要性。介入治疗,包括神经调节,速效药物治疗,如静脉注射氯胺酮(IV-KET)和艾氯胺酮(ESK),以及新兴的迷幻辅助心理治疗,提供了有希望的解决方案。本系统综述评估了这些治疗创伤后应激障碍的疗效、安全性和未来研究重点。方法:采用跨3个电子数据库的检索策略。以英文撰写的同行评议文章,重点关注成年PTSD患者的介入精神病学治疗。结果:系统回顾纳入94项研究,其中经颅磁刺激(TMS) 39项,IV-KET 8项,鼻内艾氯胺酮(IN-ESK) 3项,静脉氯胺酮(IV-KET)辅助治疗(KET-AT) 4项,艾氯胺酮(ESK)辅助治疗(ESK- at) 1项,3,4-亚甲基二氧基甲基苯丙胺辅助治疗(MDMA-AT) 14项。随机对照试验显示TMS的有效率为12.5%-80%,IV-KET为17%-67%,MDMA为50%-87%。其他治疗方法包括电休克疗法,经颅直流电刺激,以及其他药物和神经刺激治疗。大多数治疗的耐受性良好,只有轻微的、短暂的副作用。结论:本综述强调了神经调节和药物治疗PTSD的疗效、安全性和耐受性的异质性。反应率的差异反映了患者群体、治疗方案和合并症的差异。虽然重复TMS、IV-KET、ESK、KET-AT和MDMA-AT显示症状改善,但持续疗效不同,强调需要维持策略。尽管针对特定阶段的方法的直接证据有限,但这些方法在基于神经科学的命名法指导下,可以提高治疗的准确性,特别是在复杂病例中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Psychiatry and Clinical Psychopharmacology
Psychiatry and Clinical Psychopharmacology Medicine-Psychiatry and Mental Health
CiteScore
1.00
自引率
14.30%
发文量
0
期刊介绍: Psychiatry and Clinical Psychopharmacology aims to reach a national and international audience and will accept submissions from authors worldwide. It gives high priority to original studies of interest to clinicians and scientists in applied and basic neurosciences and related disciplines. Psychiatry and Clinical Psychopharmacology publishes high quality research targeted to specialists, residents and scientists in psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related sciences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信